Izencitinib
- Generic Name
- Izencitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N8
- CAS Number
- 2051918-33-1
- Unique Ingredient Identifier
- 2ZT81PV5UM
- Background
Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).
Efficacy and Safety of TD-1473 in Crohn's Disease
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 167
- Registration Number
- NCT03635112
- Locations
- 🇺🇸
PMG Research of Salisbury, Salisbury, North Carolina, United States
🇬🇧Theravance Biopharma Investigational Site, Glasgow, Scotland, United Kingdom
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 36
- Registration Number
- NCT03555617
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-1473 for Active Ulcerative Colitis (UC)
Phase 1
Completed
- Conditions
- Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT02818686
- Locations
- 🇷🇴
Theravance Biopharma Investigational Site, Bucharest, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath